Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The objective of this study was to report the clinical course of a cohort of patients with clinically amyopathic dermatomyositis (CADM) in correlation to the presence or absence of anti-melanoma differentiation-associated gene 5 (MDA-5) antibody. Five patients with CADM presented to our rheumatology unit between September 1, 2011 and March 31, 2014. We hereby present their clinical course, laboratory findings, imaging modalities, functional tests, and treatments regimens. Our cohort included five patients, with a mean age of 41.8 ± 17.7. Three patients, all anti-MDA-5 antibody positive, developed rapidly progressive interstitial lung disease (ILD) within 4.3 ± 4.5 months of presentation. Two of these patients succumbed to their disease within 30 months of diagnosis despite intensive immunosuppressive therapy. The third anti-MDA-5-positive patient with ILD is still stable, 20 months from disease onset, on massive combination therapy. One patient developed CADM associated with the anti-p155/140 antibody, a year after completing chemotherapy for non-seminomatous germ cell tumor. He presented with a benign clinical course with no evidence of ILD and no recurrence of malignancy after 20 months of follow-up. The fifth patient in our cohort, who is anti-MDA-5 negative and has no evidence of malignancy, also enjoys a benign clinical course. The presence of anti-MDA-5 antibodies in CADM patients is associated with rapidly progressive ILD and a poor prognosis. The serologic profile of patients with CADM should be routinely evaluated and integrated with clinical data in the management of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bendewald MJ, Wetter DA, Li X, Davis MD (2010) Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 146(1):26–30

    Article  PubMed  Google Scholar 

  2. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T (2011) Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158(4):675–677

    Article  CAS  PubMed  Google Scholar 

  3. Muro Y, Sugiura K, Hoshino K, Akiyama M (2012) Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 51(5):800–804

    Article  CAS  Google Scholar 

  4. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB et al (2010) Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11:223

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X et al (2012) Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 64(10):1602–1610

    Article  Google Scholar 

  6. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52(5):1571–1576

    Article  CAS  PubMed  Google Scholar 

  7. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60(7):2193–2200

    Article  CAS  PubMed  Google Scholar 

  8. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147(4):391–398

    Article  CAS  PubMed  Google Scholar 

  9. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K et al (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49(9):1713–1719

    Article  CAS  Google Scholar 

  10. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22(2):245–250

    Article  CAS  PubMed  Google Scholar 

  11. Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP (2007) Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol 57(6):937–943

    Article  PubMed  Google Scholar 

  12. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54(4):597–613

    Article  PubMed  Google Scholar 

  13. Sato S, Kuwana M, Fujita T, Suzuki Y (2013) Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23(3):496–502

    Article  CAS  PubMed  Google Scholar 

  14. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970

    Article  CAS  PubMed  Google Scholar 

  15. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666

    Article  CAS  PubMed  Google Scholar 

  16. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176(10):1026–1034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40(5):640–646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Morganroth PA, Kreider ME, Werth VP (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 62(10):1496–1501

    Article  Google Scholar 

  19. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK et al (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130(1):30–36

    Article  CAS  PubMed  Google Scholar 

  20. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66(10):1345–1349

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K et al (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46(1):25–28

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The study was supported by the Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Israel.

Disclosures

None.

Author information

Authors and Affiliations

  1. The Talpiot Medical Leadership Program and Department of Internal Medicine D, The Chaim ShebaMedical Center, Tel-Hashomer, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Bornstein Gil

  2. Rheumatology Unit, The Chaim Sheba Medical Center, Tel-Hashomer, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Lidar Merav, Langevitz Pnina & Grossman Chagai

Authors
  1. Bornstein Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lidar Merav
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Langevitz Pnina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Grossman Chagai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bornstein Gil.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gil, B., Merav, L., Pnina, L. et al. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol 35, 2125–2130 (2016). https://doi.org/10.1007/s10067-015-2928-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-2928-8

Keywords

Search

Navigation